Table 3.
Percentage of COVID-19 patients exhibiting hepatobiliary laboratory abnormalities including AST, ALT, and total bilirubin in studies completed from China.
| Hepatobiliary Laboratory Abnormalities seen in COVID-19 Patients | ||||
|---|---|---|---|---|
| Study | Number of Patients, N | AST, N (%) | ALT, N (%) | Total Bilirubin, N (%) |
| Pan L, et al. [11] | 204 | 22 (11 %) | 27 (13 %) | NA |
| Fang D, et al. [16] | 304 | 24 (8 %) | 19 (6 %) | 6 (2 %) |
| Guan W, et al. [18] | 741 | 168 (22 %) | 158 (21 %) | 76 (10 %) |
| Chen N, et al. [23] | 99 | 35 (35 %) | 28 (28 %) | 18 (18 %) |
| Xu X, et al. [30] | 62 | 10 (16 %) | 26 (20−32)+ | NA |
| Huang C et al. [31] | 41 | 15 (37 %) | 32 (21−50)+ | 11.7 (9.5−13.9)++ |
| Zhou F, et al. [21] | 189 | NA | 59 (31 %) | NA |
| Mo P, et al. [22] | 155 | 32 (24−48)++ | 23 (16−38) | NA |
| Shi H, et al. [20] | 81 | 43 (53 %) | NA | NA |
COVID-19-coronavirus disease 2019, AST-Aspartate aminotransferase, ALT- Alanine aminotransferase, ++ median in mmol/L, + median in U/L, N- number.